xestoquinone

structure given in first source; RN given refers to the (S)-isomer; RN for cpd without isomeric designation not available 5/91; isolated from the sea sponge Xestospongia sapra

Also Known As:

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chen, Chun-Lin: 1 article (11/2021)
2.	El-Shazly, Mohamed: 1 article (11/2021)
3.	Hsu, Kai-Cheng: 1 article (11/2021)
4.	Kuo, Fu-Wen: 1 article (11/2021)
5.	Lien, Ssu-Ting: 1 article (11/2021)
6.	Lu, Mei-Chin: 1 article (11/2021)
7.	Shih, Shou-Ping: 1 article (11/2021)
8.	Wang, Kuan-Chih: 1 article (11/2021)
9.	Yang, Shyh-Chyun: 1 article (11/2021)
10.	Yang, Yu-Chen S H: 1 article (11/2021)

Related Diseases

1.	Neoplasms (Cancer) 11/21/2021 - "We tested the cytotoxic activity of xestoquinone on a series of hematological cancer cell lines. " 11/21/2021 - "Molecular docking, Western blotting, and thermal shift assay verified the catalytic inhibitory activity of xestoquinone by high binding affinity to HSP-90 and Topo I/II. Our findings indicated that xestoquinone targeted leukemia cancer cells through multiple pathways, suggesting its potential application as an antileukemic drug lead." 11/21/2021 - "The pretreatment of Molt-4 cells with N-acetyl cysteine (NAC) diminished the disruption of the mitochondrial membrane potential (MMP) and apoptosis, as well as retaining the expression of both Topo I and II. In the nude mice xenograft model, the administration of xestoquinone (1 μg/g) significantly attenuated tumor growth by 31.2% compared with the solvent control. "
2.	Malaria 01/01/2009 - "The structures as well as bioactivities of compounds against the malaria parasites such as Plasmodium falciparum are discussed, including, for example, agelasine, xestoquinone, alisiaquinone, crambescidin, venturamide, dragomabin, gragonamide, viridamide, salinosporamide, chaetoxanthone, nodulisporacid, tumonoic acid, girolline, oroidin, nostocarboline, aerucyclamide, and microcylamide 7806 and its revised structure. "
3.	Leukemia 11/21/2021 - "Molecular docking, Western blotting, and thermal shift assay verified the catalytic inhibitory activity of xestoquinone by high binding affinity to HSP-90 and Topo I/II. Our findings indicated that xestoquinone targeted leukemia cancer cells through multiple pathways, suggesting its potential application as an antileukemic drug lead."
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/01/2005 - "The cytotoxicity against two human squamous cell carcinoma cell lines, A431 and Nakata, indicated that the terminal quinone structure of the polycyclic molecules was important (xestoquinone, etc.) and that the presence of a ketone group at C-3 of the opposite terminus dramatically diminished the activity (halenaquinone, etc.). "

Related Drugs and Biologics

1.	Matrix Metalloproteinases (MMPs)
2.	Solvents
3.	Ketones
4.	Cysteine (L-Cysteine)
5.	Acids
6.	girolline
7.	dragomabin
8.	nostocarboline
9.	halenaquinone
10.	oroidin